News|Articles|March 3, 2005

Nanoparticle Synthesis Process Facilitates Chiral Separations

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Creative image of embryonic stem cells, cellular therapy, 3d illustration | Image Credit: ©pinkeyes - stock.adobe.com

Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies

ByCynthia A. Challener

July 8th 2026

Scientific and technological background. Image of dna molecule with technological elements. | Image Source: ©Alex -stock.adobe.com

The Next Generation of Medicine: Personalized, Preventive, and Powered by Technology

ByAngela Strzelecki

July 8th 2026

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

What Trutakna's FDA Approval Means for Specialty Biologics

ByStephen Appezzato,Zachary Zubulake

July 7th 2026

The EMA is accelerating the approval of daraxonrasib through a phased assessment, which could reshape submission planning in the EU.

Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

ByZachary Zubulake

July 7th 2026

Novartis has agreed to acquire Myricx Bio

Why Are Drugmakers Racing to Acquire ADC Payload Platforms?

ByZachary Zubulake

July 6th 2026

Nanoparticle Synthesis Process Facilitates Chiral Separations

Related Content

Overcoming Raw-Material Variability Challenges for Autologous Adoptive Cell Therapies

The Next Generation of Medicine: Personalized, Preventive, and Powered by Technology

What Trutakna's FDA Approval Means for Specialty Biologics

Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

Why Are Drugmakers Racing to Acquire ADC Payload Platforms?

Trending on Pharmaceutical Technology

What FDA's AI Warning Letter Tells Us About GMP Accountability

Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

Why Are Drugmakers Racing to Acquire ADC Payload Platforms?

What Trutakna's FDA Approval Means for Specialty Biologics

The Role of Standards in the Drug Supply Chain